Nest.Bio Ventures is the famous VC, which was founded in 2016. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the Boston.
The typical startup value when the investment from Nest.Bio Ventures is 100-500 millions dollars. The fund is constantly included in 2-6 deals per year. The high activity for fund was in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars. This Nest.Bio Ventures works on 18 percentage points less the average amount of lead investments comparing to the other organizations.
Besides them, we counted 4 critical employees of this fund in our database.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Nest.Bio Ventures, startups are often financed by Vivo Capital, Viventures, U.S. Department of Defense. The meaningful sponsors for the fund in investment in the same round are Viventures, Sequoia Capital China, Qiming Venture Partners. In the next rounds fund is usually obtained by Sequoia Capital China, Legend Star, LYFE Capital.
Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Senti Biosciences, HiFiBiO, RootPath Genomics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. When startup sums 1 of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Medical, Biopharma.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Able Partners | New York, New York, United States |
| Argosy Capital | Pennsylvania, United States, Wayne |
| Authentic Ventures | California, Oakland, United States |
| Corsa Ventures | Austin, Texas, United States |
| Crescendo Venture Partners | Israel, Tel Aviv, Tel Aviv |
| Divine Capital Markets | New York, New York, United States |
| Krungsri Finnovate | Bangkok, Krung Thep, Thailand |
| Lanhua Tengge Touzi | - |
| LG Innovation Ventures | California, San Jose, United States |
| Manchester Technology Fund | England, Manchester, United Kingdom |
| NYC Media Lab | Brooklyn, New York, United States |
| Pros Partners | China, Shanghai |
| RONAholdings | California, San Francisco, United States |
| Ruichuang Touzi | China, Shanghai |
| Semiconductor Manufacturing International | China, Shanghai |
| Shanhua Touzi | China, Guangdong, Guangzhou |
| The Lawrence J. Ellison Revocable Trust | California, United States, Walnut Creek |
| The Pyle Group | Madison, United States, Wisconsin |
| Yangzi Xinrui | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
DeepVerse | $1M | 14 Mar 2023 | Shanghai, Shanghai, China | ||
PAQ Therapeutics | $30M | 15 Jul 2021 | Cambridge, Massachusetts, United States | ||
Engine Biosciences | $43M | 26 May 2021 | San Francisco, California, United States | ||
RootPath Genomics | $11M | 05 Jan 2020 | Cambridge, Massachusetts, United States | ||
Platelet BioGenesis | $26M | 09 Sep 2019 | Newton, Massachusetts, United States | ||
RootPath Genomics | $7M | 30 Aug 2018 | Cambridge, Massachusetts, United States | ||
POINTS Technology | $8M | 20 Jul 2018 | Singapore, Central, Singapore | ||
Astrocyte Pharmaceuticals | $2M | 06 Jun 2018 | Cambridge, Massachusetts, United States | ||
HiFiBiO | $37M | 16 May 2018 | Ile-de-France |
– PAQ Therapeutics is a biotechnology company advancing a new approach to restoring health and curing disease through autophagy.
– The company announced the closing of a $30m Series A round.
– Sherpa Healthcare Partners led the round with participation from Huagai Capital, MSA Capital, and MRL Ventures Fund as well as seed investors Nest.Bio Ventures and Matrix Partners China.
– The funding will be used to advance the company’s ATTEC platform and progress its pipeline programs.
– Engine Biosciences announced the successful completion of an oversubscribed $43m Series A funding round.
– Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.
– This round was led by Polaris Partners and also included new investors Invus and one of the world’s premier institutional investors, based in Singapore.
– Existing investors also participated in the Series A, which included 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio.
– Amy Schulman, Managing Partner at Polaris Partners, has joined the Engine Biosciences Board of Directors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
DeepVerse | $1M | 14 Mar 2023 | Shanghai, Shanghai, China | ||
PAQ Therapeutics | $30M | 15 Jul 2021 | Cambridge, Massachusetts, United States | ||
Engine Biosciences | $43M | 26 May 2021 | San Francisco, California, United States | ||
RootPath Genomics | $11M | 05 Jan 2020 | Cambridge, Massachusetts, United States | ||
Platelet BioGenesis | $26M | 09 Sep 2019 | Newton, Massachusetts, United States | ||
RootPath Genomics | $7M | 30 Aug 2018 | Cambridge, Massachusetts, United States | ||
POINTS Technology | $8M | 20 Jul 2018 | Singapore, Central, Singapore | ||
Astrocyte Pharmaceuticals | $2M | 06 Jun 2018 | Cambridge, Massachusetts, United States | ||
HiFiBiO | $37M | 16 May 2018 | Ile-de-France |
